Luca Boldrini

Università Cattolica del Sacro Cuore, Roma, Italia

Luca Boldrini obtained his Medical Degree and completed his residency program in Radiotherapy at the Università Cattolica del Sacro Cuore of Rome, Italy. 

He currently works as Radiation Oncologist at the Fondazione Policlinico Universitario “A. Gemelli” IRCCS - Università Cattolica del Sacro Cuore of Rome, where he is involved in the MRI guided radiotherapy research program.

His primary research interests include MRI guided radiotherapy, radiomics, imaging applications in the frame of personalised medicine and innovative technologies implementation in cancer care.

He is author of numerous scientific publication, books, and e-publications. 
He is clinical coordinator of the radiomics research program of the Knowledge Based Oncology Lab (KBO Lab) of Rome, Italy.

He is currently a Ph.D. student in Oncological Sciences focusing on “Radiation Oncology, imaging and technological innovation” at the Università Cattolica del Sacro Cuore of Rome, Italy and member of several national and
international scientific associations.

dont miss

Radiomics applications rectal cancer: the MRIdian perspective

The seminar will describe the potentialities of low T MRI guided hybrid Radiotherapy from a radiomics perspective. The talk will be focused on radiomics based prediction models for complete clinical response in rectal cancer patients undergoing neoadjuvant chemoradiotherapy.

Luca Boldrini will be speaking in the following theatre:

Theatre 10 - Wednesday 13.15 - 13.45: Radiomics applications rectal cancer: the MRIdian perspective

EVEN MORE SEMINARS

  • Professor Zoë Winters: Speaking at the Oncology Convention

    Professor Zoë Winters
    University College London

    Is breast conserving surgery a future treatment for multiple ipsilateral breast cancers?

  • Dr Richter-Heine: Speaking at the Oncology Convention

    Dr Richter-Heine
    Praxisgemeinschaft im Camparihaus

    Benefits of supporting medical garments in breast surgery

  • Mr Richard Steyn: Speaking at the Oncology Convention

    Mr Richard Steyn
    UK Lung Cancer Coalition / University Hospitals Birmingham NHS Foundation Trust

    Doubling Five-Year UK Lung Cancer Survival to 25% by 2025

  • Khurum Khan: Speaking at the Oncology Convention

    Khurum Khan
    Royal Marsden NHS Foundation Trust

    Biomarkers of response and/or resistance to targeted therapies in refractory mCRC

  • Kate Casey: Speaking at the Oncology Convention

    Kate Casey
    The Leeds Gamma Knife Centre

    ICON LEKSELL GAMMA KNIFE STEREOTACTIC RADIOSURGERY